# Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

Study · id `cardio:ct-nct03001817` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03001817](<https://clinicaltrials.gov/study/NCT03001817>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03001817

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 551 participants.

## Technical summary

Registry record NCT03001817. Randomized; triple masking; primary purpose treatment. Start 2016-11-28 (actual); primary completion 2019-06-24 (actual). Results posted on 2022-11-30.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 551 participants (enrolled count; ClinicalTrials.gov record NCT03001817, source copy `cardio:ctgov-nct03001817-2022-11-30`, retrieved 2026-10-31)
- Started: 2016-11-28 (actual) (ClinicalTrials.gov record NCT03001817, source copy `cardio:ctgov-nct03001817-2022-11-30`, retrieved 2026-10-31)
- Primary completion: 2019-06-24 (actual) (ClinicalTrials.gov record NCT03001817, source copy `cardio:ctgov-nct03001817-2022-11-30`, retrieved 2026-10-31)
- Completion: 2019-06-24 (actual) (ClinicalTrials.gov record NCT03001817, source copy `cardio:ctgov-nct03001817-2022-11-30`, retrieved 2026-10-31)
- Results first posted: 2022-11-30 (ClinicalTrials.gov record NCT03001817, source copy `cardio:ctgov-nct03001817-2022-11-30`, retrieved 2026-10-31)
- Countries: United States; Belarus; Bulgaria; Czechia; Georgia; Hungary; Poland; Russia; Ukraine (ClinicalTrials.gov record NCT03001817, source copy `cardio:ctgov-nct03001817-2022-11-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03001817-2022-11-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
- Condition: Severe Hypertriglyceridemia
- Intervention (Drug): K-877
- Intervention (Drug): Fenofibrate
- Intervention (Drug): Placebo (for K-877)
- Intervention (Drug): Placebo (for Fenofibrate)
- Lead sponsor: Kowa Research Institute, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Kowa Research Institute, Inc. (`cardio:org-kowa-research-institute-inc`)

## Provenance

Content hash: 9956d4d154c72f03e911c201981e2b3aa915af1a4b6841e261fe7a7e13f0a0a9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
